Randomized phase II trial of uracil/tegafur and cisplatin versus pemetrexed and cisplatin with concurrent thoracic radiotherapy for locally advanced unresectable stage III non-squamous non-small cell lung cancer: NJLCG1001
Makoto Maemondo(Miyagi Prefectural Hospital Organization), Hisashi Tanaka(Hirosaki University), Eisaku Miyauchi(Tohoku University), Haruo Matsushita(Miyagi Prefectural Hospital Organization), Masachika Akiyama(Iwate Medical University), Taku Nakagawa(Saint John's Health Center), Jun Sakakibara‐Konishi(Hokkaido University), Akira Inoue(Tohoku University Hospital), Fumiaki Takahashi(Iwate Medical University), Hiroyuki Minemura(Fukushima Medical University), Ryotaro Igusa(Miyagi Prefectural Hospital Organization), Tatsuro Fukuhara(Miyagi Prefectural Hospital Organization), Shunichi Sugawara(Sendai Kousei Hospital), Keisuke Fujimoto(Iwate Medical University), Yukihiro Toi(Sendai Kousei Hospital), Atsushi Nakamura(Sendai Kousei Hospital), Naruo Yoshimura(Tohoku University), Yoshiaki Mori(Iwate Prefectural Central Hospital), Ryosuke Chiba(Iwate Medical University), Kana Watanabe(Miyagi Prefectural Hospital Organization)
Cited by 6
Related Papers
Gefitinib or Chemotherapy for Non–Small-Cell Lung Cancer with Mutated EGFR
|New England Journal of Medicine|2010|5.6k
Pembrolizumab plus Chemotherapy for Squamous Non–Small-Cell Lung Cancer
|New England Journal of Medicine|2018|3.7k
Adjuvant atezolizumab after adjuvant chemotherapy in resected stage IB–IIIA non-small-cell lung cancer (IMpower010): a randomised, multicentre, open-label, phase 3 trial
|The Lancet|2021|1.5k
Osimertinib with or without Chemotherapy in <i>EGFR</i> -Mutated Advanced NSCLC
|New England Journal of Medicine|2023|695